Exploring Cardio-Metabolic Risk and Aspirin: Key Insights for Indian Patients

Cardiometabolic Burden in India

Prevalence of Cardiometabolic Conditions

India faces a significant cardiometabolic burden, impacting nearly 30% of its population. This issue is exacerbated by the rising prevalence of early-onset diabetes, hypertension, dyslipidaemia, and obesity that extends beyond traditional BMI measurements. Among individuals categorized as metabolically obese non-obese (MONO) and metabolically obese obese (MOO), the relative risk of cardiovascular disease (CVD) increases by approximately 77% (OR 1.77) and 92% (OR 1.92), respectively. Furthermore, central obesity in individuals with normal weight raises the risk of hypertension by around 55% (aOR≈1.55). These risk factors contribute to the early onset of coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ASCVD) among young and middle-aged Indians.

The Role of Aspirin in Cardiometabolic Health

In the context of metabolic dysfunction and early vascular disease, aspirin’s antiplatelet and anti-inflammatory properties may provide selective preventive benefits for carefully stratified cardiometabolic patients.

Pathophysiological Interactions: Metabolic Dysfunction to Thrombosis

Impact of Metabolic Dysfunction

The metabolic dysfunction observed in Asian Indians is not merely a collection of risk factors; it represents an active biological state that accelerates endothelial injury and atherothrombosis. Factors such as obesity, insulin resistance, and dyslipidaemia contribute to a pro-inflammatory and pro-thrombotic environment characterized by low adiponectin levels, high leptin levels, elevated C-reactive protein (CRP), small-dense low-density lipoprotein (LDL), and increased plasminogen activator inhibitor-1 (PAI-1). This milieu drives endothelial dysfunction, impaired fibrinolysis, and early cardiovascular events.

Aspirin’s Mechanism of Action

Given that inflammation and thrombosis are central to cardiometabolic risk, an agent that targets this biological intersection is clinically relevant. Aspirin, widely used in managing atherosclerosis and acute coronary syndrome (ACS), irreversibly inhibits COX-1, which suppresses thromboxane A₂-mediated platelet activation and moderates the coagulation cascade influenced by thrombin, ADP, and TP-receptor signaling. By mitigating both inflammatory and platelet pathways, aspirin effectively intervenes at this critical junction.

Aspirin in Cardiovascular Risk Prevention: Evidence Review

Insights from ASCEND Study

The ASCEND study provides valuable insights into whether aspirin can prevent first cardiovascular events in high-risk cardiometabolic patients. Conducted with 15,480 adults diagnosed with diabetes—a well-established high-risk group without evident CVD—the trial randomized participants to receive either 100 mg of aspirin daily or a placebo over a period of 7.4 years. The results indicated a 12% relative reduction in major cardiovascular events (absolute reduction of 1.1%), nearly balanced by an increase in absolute bleeding risk of 0.9%. These findings emphasize the need for careful individualization of aspirin use in primary prevention, particularly for cardiometabolic patients like those with diabetes.

Aspirin’s Potential in India

In India, where the accumulation of cardiometabolic risks occurs earlier and significantly increases ASCVD risk among younger and middle-aged adults, the potential benefits of aspirin may be even more pronounced, especially for individuals with a lower baseline bleeding risk.

Guidance for Aspirin Use in Practice

Recommendations for Aspirin Administration

The following table outlines key recommendations for aspirin use:

Practical Decision-Making Framework

Consider a case scenario of a 47-year-old Indian male who has type 2 diabetes (T2D), hypertension, and central obesity, along with elevated CRP and a history of intermittent smoking. Despite receiving lipid-lowering therapy, his LDL-C levels have not met guideline targets. This profile indicates a multi-risk cardiometabolic individual with an increased risk of atherosclerosis.

Assessing Bleeding Risk

The patient has no history of gastrointestinal bleeding, peptic ulcer disease, or anticoagulant therapy, and possesses normal renal function, with an age below 70 years, suggesting a low risk of bleeding.

Clinical Recommendations

In patients with multiple cardiometabolic risks and a low propensity for bleeding, low-dose aspirin may be considered following shared decision-making. This approach should balance the potential ASCVD benefits against the risks of bleeding. Resources like AspirinGuide can assist clinicians in estimating bleeding risk and facilitating shared decision-making.

Conclusion

In Indian patients facing a high cardiometabolic burden, the intersection of metabolic dysfunction, inflammation, and thrombosis underscores the potential for aspirin’s anti-inflammatory and antiplatelet effects to provide targeted cardiovascular prevention benefits. When utilized within a risk-based framework and with careful assessment of bleeding risk, aspirin may be a viable option for appropriately stratified cardiometabolic patients seeking protection against cardiovascular events.